AstraZeneca Shares Climb 7% After Strong Results and Savings Plan

AstraZeneca, whose COVID-19 vaccine was among the world's most recognized, is back in the spotlight.

After the drugmaker delivered better-than-expected results and introduced a sizable cost-saving program, its shares climbed close to 7% on Friday.

Optimism is building that the oncology side of the business can offset the sales erosion caused by older medicines facing cheaper generic competition.

What Got Investors Excited About AstraZeneca's Results

Revenue for the third quarter advanced 7%, reaching $16.21 billion and coming in ahead of expectations. Core profit of $2.79 per share topped the $2.59 projection.

Cancer medicines did the heavy lifting. Oncology revenue increased 17%, with Enhertu climbing 35% and Imfinzi up 26%, as detailed in the earnings release.

Yet not all the news was positive. Farxiga, an important diabetes and heart treatment, saw sales slide 25% as generic competition grew tougher. A breast cancer trial of Etcamah missed its primary endpoint, and a lung cancer study was discontinued.

Now the company is targeting $1.5 billion in annual savings, mostly for research, while the restructuring itself could involve up to $2 billion in upfront costs.

AstraZeneca ($AZN) has begun a restructuring effort expected to save $1.5B a year and produce up to $2B in one-time charges over the next three years. The savings are to be reinvested in a drug pipeline of more than 180 projects. — Wall St Engine, October 30, 2026

AstraZeneca's Rationale for Pushing Into AI

AI is meant to help AstraZeneca spot promising drug targets and make costly clinical studies more efficient.

Modella AI has been acquired, and an agreement with insitro targets new therapies for liver and heart disease.

AstraZeneca counts more than 17,000 AI-certified employees and about 1,000 active pilots. Whether those efforts will pay off financially has yet to be established.

“With multiple potential blockbuster assets in late-stage development and transformative technologies scaling rapidly, we are on track to deliver our 2030 ambition.” — Pascal Soriot, AstraZeneca CEO

That target equals $80 billion in annual revenue by 2030.

Where AstraZeneca Shares Could Head Next

By Friday's close, AstraZeneca shares were back above the previous £131.34 resistance level.

On the charts, the next objective sits at £145.38, with the February peak near £157.30 beyond that.

The move higher was accompanied by above-average volume, giving the breakout extra weight. Still, RSI above 70 points to momentum that may be overdone. A drop under £131.34 would damage the bullish argument.

The optimism will face a test when next year's drug trial data arrive.